Pegvisomant. Treatment of acromegaly growth hormone receptor antagonist

Drugs of the Future

Volumn 24, Issue 9, 1999, Pages 969-973

  Rabasseda, X ^a   Leeson, P ^a  

^a PROUS SCIENCE   (Spain)

Author keywords

[No Author keywords available]

Indexed keywords

GROWTH HORMONE; GROWTH HORMONE RECEPTOR; HORMONE RECEPTOR BLOCKING AGENT; PEGVISOMANT; SOMATOMEDIN C; UNCLASSIFIED DRUG;

ACROMEGALY; ADULT; ARTICLE; BINDING COMPETITION; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DOUBLE BLIND PROCEDURE; DRUG EFFECT; DRUG RECEPTOR BINDING; DRUG TOLERANCE; GROWTH HORMONE RELEASE; HORMONE RECEPTOR INTERACTION; HUMAN; PHASE 3 CLINICAL TRIAL; RANDOMIZED CONTROLLED TRIAL;

EID: 0032728224     PISSN: 03778282     EISSN: None     Source Type: Journal    
DOI: 10.1358/dof.1999.024.09.549506     Document Type: Article

References (28)

1. NIDDK (National Institute of Diabetes and Digestive and Kidney Diseases). Acromegaly. NIH Publication No. 95-3924, 1995.
2. Melmed, S. Acromegaly. New Engl J Med 1990, 322: 966-77.
3. Eastman, R.C., Gorden, P., Glatstein, E., Roth, J. Radiation therapy of acromegaly. Endocrinol Metab Clin North Am 1992, 21: 693-711.
4. Krishna, A.Y., Phillips, L.S. Management of acromegaly: A review. Am J Med Sci 1994, 308: 370-5.
5. Bednarek-Tupikowska, G., Bohdanowicz-Pawlak, A., Bolanowski, M., Jedrzejak, J., Milewicz, A. Results of treatment for acromegaly with long-acting bromocriptine. Endokrynol Pol 1993, 44: 161-8.
6. Newman, C.B. Medical therapy for acromegaly. Endocrinol Metab Clin North Am 1999, 28: 171-90.
7. Gillespie, T.J., Erenberg, A., Kim, S., Dong, J., Taylor, J.E., Hau, V., Davis, T.P. Novel somatostatin analogs for the treatment of acromegaly and cancer exhibit improved in vivo stability and distribution. J Pharmacol Exp Ther 1998, 285: 95-104.
8. Newman, C.B., Melmed, S., Snyder, P.J., Young, W.F., Boyajy, L.D., Levy, R., Stewart, W.N., Klibanski, A., Molitch, M.E., Gagel, R.F. Safety and efficacy of long-term octreotide therapy of acromegaly: Results of a multicenter trial in 103 patients. A clinical research center study. J Clin Endocrinol Metab 1995, 80: 2768-75.
9. Acromegaly Therapy Consensus Development Panel. Consensus statement: Benefits versus risks of medical therapy for acromegaly. Am J Med 1994, 97: 468-73.
10. Maamra, M., Von Laue, S., Simon, S., Justice, S., Finidori, J., Dower, S.K., Ross, R.J.M. The antagonist action of B2036 on growth hormone signalling is independent of receptor internalisation. J Endocrinol 1999, 160(Suppl.): Abst P168.
11. Maamra, M., Finidori, J., Von Laue, S., Simon, S., Justice, S., Webster, J., Dower, S.K., Ross, R.J.M. GH, the GH antagonist (Trovert), and GH receptor (GHR) trafficking studied by dual fluorescent confocal microscopy. 81st Annu Meet Endocr Soc (June 12-15, San Diego) 1999, Abst P1-95.
12. Flyvbjerg, A., Bennett, W.F., Rasch, R., Kopchick, J.J., Scarlett, J.A. Inhibitory effect of a growth hormone receptor antagonist (G120K-PEG) on renal enlargement, glomerular hypertrophy, and urinary albumin excretion in experimental diabetes in mice. Diabetes 1999, 48: 377-82.
13. Flyvbjerg, A., Bennett, W., Rasch, R., Kopchick, J.J., Scarlett, J.A. Effect of a long-acting growth hormone receptor antagonist (G120K-PEG) on renal enlargement, glomerular hypertrophy and urinary albumin excretion in experimental diabetes in mice. Eur J Endocrinol 1998, 138(Suppl. 1): Abst 10.
14. Roshan, S.Y., McCutcheon, I.E., Bennett, W.F., Hill, H.L., Scarlett, J.A., Flyvbjerg, A., Friend, K.E. The growth hormone receptor antagonist B2036PEG (Trovert) inhibits the growth of breast cancer xenografts in nude mice. 81st Annu Meet Endocr Soc (June 12-15, San Diego) 1999, Abst PS-122.
15. McCutcheon, I.E., Bennett, W.F., Hill, H.L., Li, T., Radinsky, R., Scarlett, J.A., Zhang, B.M., Friend, K.E. The growth hormone receptor antagonist B2036PEG (Trovert) inhibits the growth of meningioma xenografts in nude mice. Proc Amer Assoc Cancer Res 1999, 40: Abst 4047.
16. Coffin, V., Bernichtein, S., Carriere, O., Kopchick, J.J., Bennett, W.F., Kelly, P.A. The human growth hormone antagonist B2036-PEG (Trovert™) has no agonistic or antagonistic effect on the human prolactin receptor. 81st Annu Meet Endocr Soc (June 12-15, San Diego) 1999 Abst P1-94.
17. Khan, M.N., Lu, Y.R., Pham, K., Zib, K. Development of a sensitive radioimmunoassay for the quantification of B2036-PEG in human serum: Validation and its application in a phase I study. Pharm Res 1997, 14(11, Suppl.): Abst 4160.
18. Rodvold, K.A., Bennett, W.F., Zib, K.A. Single-dose safety and pharmacokinetics of B2036-PEG (Somavert) after subcutaneous administration in healthy volunteers. J Clin Pharmacol 1997, 37: Abst 50.
19. Rodvold, K.A., van der Lely, A.J. Pharmacokinetics and pharmacodynamics of B2036-PEG, a novel growth hormone receptor antagonist, in acromegalic subjects. 81st Annu Meet Endocr Soc (June 12-15, San Diego) 1999, Abst P1-49.
20. Thorner, M.O., Strasburger, C.J., Wu, Z., Straume, M., Bidlingmaier, M., Pezzoli, S.S., Zib, K., Scarlett, J.C., Bennett, W.F. Growth hormone (GH) receptor blockade with a PEG-modified GH (B2036-PEG) lowers serum insulin-like growth factor-I but does not acutely stimulate serum GH. J Clin Endocrinol Metab 1999, 84:2098-103.
21. Trainer, P.J., Drake, W.M., Conrich, L., Monson, J.P., Besser, G.M. Successful treatment of acromegaly with a growth hormone receptor antagonist (Trovert™). J Endocrinol 1998, 159(Suppl.): Abst OC23.
22. Barkan, A., Dimaraki, E., Besser, G.M. et al. Treatment of acromegaly with B2036-PEG, a growth hormone receptor antagonist. 81st Annu Meet Endocr Soc (June 12-15, San Diego) 1999, Abst OR14-6.
23. Trainer, P.J., Drake, W.M., Besser, M. Growth hormone receptor antagonist therapy for acromegaly. 81st Annu Meet Endocr Soc (June 12-15, San Diego) 1999, Abst S21-3.
24. Trainer, P.J., Drake, W.M., Conrich, L., Taylor, N.F., Besser, G.M., Monson, J.P. Modulation of cortisol metabolism by a growth hormone receptor antagonist (Trovert ™) in patients with acromegaly. J Endocrinol 1999, 160(Suppl.): Abst OC33.
25. Morrison, K.M., Bidlingmaier, M., Stadler, S., Wu, Z., Zib, K., Bennett, W.F., Strasburger, C.J. Monitoring the treatment of acromegaly with B2036-PEG using acid labile subunit (ALS) levels. 81st Annu Meet Endocr Soc (June 12-15, San Diego) 1999, Abst P1-48.
26. Trainer, P.J., Besser, G.M., Klibanski, A., Freda, P.U., Melmed, S. A phase III study of B2036, a growth hormone antagonist, in the treatment of acromegaly. 81st Annu Meet Endocr Soc (June 12-15, San Diego) 1999, Abst P1-46.
27. Rose, D.R. Jr., Clemmons, D.R. Growth hormone receptor antagonist induces improvement in insulin resistance in acromegaly. 81st Annu Meet Endocr Soc (June 12-15, San Diego) 1999, Abst P1-47.
28. Trovert receives Orphan Drug designation for acromegaly. DailyDrugNews.com August 13, 1997.